Neurocrine Biosciences
NBIX
#1366
Rank
A$23.46 B
Marketcap
A$235.39
Share price
0.84%
Change (1 day)
20.10%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): A$6.63

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is A$6.52. In 2024 the company made an earnings per share (EPS) of A$5.12 an increase over its 2023 EPS that were of A$3.84.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$6.6329.64%
2024A$5.1233.07%
2023A$3.8457.76%
2022A$2.4469.47%
2021A$1.44-78.21%
2020A$6.60990%
2019A$0.6181.82%
2018A$0.33-113.5%
2017A-$2.470.62%
2016A-$2.4557.28%
2015A-$1.5625.61%
2014A-$1.2418.84%
2013A-$1.04-1085.71%
2012A$0.11

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Repligen
RGEN
A$0.04541-99.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$2.67-59.02%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
A-$92.33-1,515.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$31.06 376.06%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$2.05-68.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
A$2.60-60.09%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$2.59-60.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
A-$3.07-147.10%๐Ÿ‡บ๐Ÿ‡ธ USA